Am J Gastroenterol
- CHIRAPONGSATHORN S, Chang A, Malikhao S, Wanichagool D, et al
One versus five days of octreotide infusion for acute esophageal variceal
bleeding: a randomized controlled trial.
Am J Gastroenterol. 2025 Oct 15. doi: 10.14309/ajg.0000000000003791.
Biochem Biophys Res Commun
- FU J, Chen T, Fang X, Zhang S, et al
Immune cell subsets as therapeutic targets in liver fibrosis: from mechanisms to
translational applications.
Biochem Biophys Res Commun. 2025;785:152682.
BMC Cancer
- QIN Y, Zhou J, Li S, Liu X, et al
SLIT2 modulates NMIIA to regulate mitophagy and suppress hepatocellular carcinoma
progression.
BMC Cancer. 2025;25:1561.
- CHEN J, Hu Z, Li H, Su R, et al
Machine learning predicts post-transplant muscle loss in hepatocellular carcinoma
patients without sarcopenia.
BMC Cancer. 2025;25:1565.
BMC Gastroenterol
- BEHZAD C, Shateri Z, Motamed N, Maadi M, et al
Association of cardiometabolic index with non-alcoholic fatty liver disease among
Iranian adults of the amol cohort study.
BMC Gastroenterol. 2025;25:729.
Dig Dis Sci
- TAN Y, Zhang X, Wang J, Xiao X, et al
EphA3/EFNA3 Reverse Signalling Promotes Epithelial-to-Mesenchymal Transition via
ERK Pathway to Facilitate Colorectal Cancer Metastasis.
Dig Dis Sci. 2025;70:3356-3368.
- HAIMI M, Baker FA, Vinker S, Safadi R, et al
Association Between High FIB-4 Score and the Risk of Malignancy Development and
Mortality: A Retrospective Longitudinal Case-Control Study.
Dig Dis Sci. 2025;70:3525-3537.
Eur J Pediatr
- HUI WF, Deep A
Interpreting liver function markers in children on continuous renal replacement
therapy for acute liver failure.
Eur J Pediatr. 2025;184:675.
Gut
- GAO C, Wang Y, Zhou G, Shi P, et al
KIF1Bbeta suppresses hepatocellular carcinoma by transporting and secreting FBLN5 to
attenuate the integrin pathway.
Gut. 2025 Oct 13:gutjnl-2025-336230. doi: 10.1136/gutjnl-2025-336230.
Hepatology
- SALLMON H, Laufer G, Kurath-Koller S, Kramer P, et al
Letter to the editor: Esophageal varices in Fontan patients - circulatory or
hepatic failure?
Hepatology. 2025 Oct 13. doi: 10.1097/HEP.0000000000001573.
- ZHANG X, Gong H, Gu K, Chen D, et al
Letter to the Editor: Re-evaluating the clinical relevance of the RIPPLY1-TBX19
Axis in CTNNB1-Mutant hepatocellular carcinoma.
Hepatology. 2025 Oct 14. doi: 10.1097/HEP.0000000000001572.
- PATIDAR KR, Sharma P
Time to focus on POCUS For AKI management in cirrhosis.
Hepatology. 2025 Oct 16. doi: 10.1097/HEP.0000000000001583.
- KHALID MB, Ilyas SI
Surgical resection for hepatocellular carcinoma: Leave no TACE?
Hepatology. 2025;82:1039-1040.
- WANG X, Zhang L, Dong B
Molecular mechanisms in MASLD/MASH-related HCC.
Hepatology. 2025;82:1303-1324.
- NOUREDDIN M
MASH clinical trials and drugs pipeline: An impending tsunami.
Hepatology. 2025;82:1325-1340.
- UNALP-ARIDA A, Ruhl CE
Prevalence of metabolic dysfunction-associated steatotic liver disease and
fibrosis defined by liver elastography in the United States using National Health
and Nutrition Examination Survey 2017-March 2020 and August 2021-August 2023
data.
Hepatology. 2025;82:1256-1273.
- NEWTON KP, Jayasekera D, Blackford AL, Behling C, et al
Longitudinal response to standard of care in pediatric metabolic
dysfunction-associated steatotic liver disease: Rates of improvement and
worsening, and factors associated with outcomes.
Hepatology. 2025;82:1198-1210.
- ROUSSEAU D, Bonnafous S, Soysouvanh F, Sarrail D, et al
CD44 in myeloid cells is a major driver of liver inflammation and injury in
alcohol-associated liver disease.
Hepatology. 2025;82:1211-1228.
- SERPER M, Tang H, Zhang S, McCullough A, et al
Clinical outcomes and care for spontaneous bacterial peritonitis: A national
cohort study.
Hepatology. 2025;82:1187-1197.
- WANG L, Dong W, Fan L, Kong H, et al
Repression of the ERRgamma-CYP2E1 pathway by FGF4 mitigates alcohol-associated liver
injury.
Hepatology. 2025;82:1138-1154.
- MOECKLI B, Wassmer CH, El Hajji S, Kumar R, et al
Determining safe washout period for immune checkpoint inhibitors prior to liver
transplantation: An international retrospective cohort study.
Hepatology. 2025 Mar 5. doi: 10.1097/HEP.0000000000001289.
- HARTMANN P, Mouzaki M, Hassan S, Kehar M, et al
Call to action-Pediatric MASLD requires immediate attention to curb health
crisis.
Hepatology. 2025;82:1341-1351.
J Clin Oncol
- FRANSSEN S, Rousian M, Filipe WF, Buisman FE, et al
Hepatic Arterial Infusion Pump Chemotherapy in Patients With Unresectable
Intrahepatic Cholangiocarcinoma-PUMP-2 Trial.
J Clin Oncol. 2025 Oct 13:JCO2500923. doi: 10.1200/JCO-25-00923.
J Gastroenterol
- NAKADAI Y, Ojiro K, Kasuga R, Chu PS, et al
Validation of novel scoring systems for acute decompensated cirrhosis identifies
PBC as an independent poor prognostic factor: a single-center Japanese cohort
study.
J Gastroenterol. 2025 Oct 12. doi: 10.1007/s00535-025-02310.
J Gastroenterol Hepatol
- AGARWAL A, Pachisia AV, Agarwal S, Mehta S, et al
Celiac Disease and Its Impact on Liver-Related Outcomes in Patients With
All-Cause Cirrhosis: The CELIHEP Study.
J Gastroenterol Hepatol. 2025 Oct 16. doi: 10.1111/jgh.70082.
- XU L, Liu J
Comment on Impact of Renin-Angiotensin-Aldosterone System Inhibitors on
Liver-Related Events and Mortality in Patients With Cirrhosis: A Meta-Analysis of
Real-World Evidence.
J Gastroenterol Hepatol. 2025 Oct 16. doi: 10.1111/jgh.70114.
J Hepatol
- GARG P, Verma N, Jalan R
Reply to: RIPK3 in acutely decompensated cirrhosis: prognostic promise and
analytic pitfalls.
J Hepatol. 2025 Oct 9:S0168-8278(25)02549-8. doi: 10.1016/j.jhep.2025.
- THEVENOT T, Desmarets M, Tio G
Primary prophylaxis of spontaneous bacterial peritonitis using rifaximin in
patients with severe cirrhosis and ascites, not the end of the story?
J Hepatol. 2025 Oct 9:S0168-8278(25)02551-6. doi: 10.1016/j.jhep.2025.
- WEDEMEYER H, Tacke F, Newsome P, Ratziu V, et al
The first human xenogeneic liver transplantation - A landmark event, but what
does it mean for hepatology?
J Hepatol. 2025 Oct 9:S0168-8278(25)02496-1. doi: 10.1016/j.jhep.2025.
- TELLEZ L, Donate J, Guerrero A, Beraza IA, et al
Early portopulmonary hypertension predicts mortality in patients with cirrhosis:
insights from the PORTO-DETECT cohort.
J Hepatol. 2025 Oct 9:S0168-8278(25)02490-0. doi: 10.1016/j.jhep.2025.
- QIAN S, He Y
Alcohol consumption potentiates second-hit events in HBV-induced hepatocellular
carcinoma.
J Hepatol. 2025 Oct 10:S0168-8278(25)02548-6. doi: 10.1016/j.jhep.2025.
Oncogene
- CHEN Q, Liang Y, Li Y, Li X, et al
PSME3 drives Tregs infiltration and anti-PD1 resistance in hepatocellular
carcinoma by regulating FBXL7/PTEN-mediated metabolic reprogramming.
Oncogene. 2025 Oct 15. doi: 10.1038/s41388-025-03593.
PLoS One
- SHEN P, Xiong H, Luo QH, Ding YF, et al
Investigating the common genetic basis between inflammatory bowel disease and
metabolic syndrome through genomic structural equation modeling.
PLoS One. 2025;20:e0334456.
- WANG Q, Su Y, Niu J, Wang Y, et al
Nonlinear association between TyG-BMI and MAFLD: A cross-sectional study.
PLoS One. 2025;20:e0331140.
- CORBALAN JJ, Jagadeesan P, Nickels JT Jr
Humanized monoacylglycerol acyltransferase 2 mice on a high-fat diet exhibit
impaired liver detoxification during metabolic dysfunction-associated steatotic
liver disease.
PLoS One. 2025;20:e0334213.
- TAKAURA K, Tsuchiya K, Taguchi M, Tokunaga Y, et al
Clinical outcome of radiofrequency ablation in patients with hepatocellular
carcinoma aged 80 years and older.
PLoS One. 2025;20:e0334712.
- SCHREINER AD, Zhang J, Gebregziabher M, Marsden J, et al
The association of race with time to severe liver disease diagnoses.
PLoS One. 2025;20:e0334016.
- WANG Y, Cai T, Chen Y, Liu W, et al
KIF18A induces the EMT process of hepatoma cells through the 5-LOX-dependent
arachidonic acid pathway.
PLoS One. 2025;20:e0333385.
- YANG X, Wang G, Min Z, Lv L, et al
The prognostic value of the direct bilirubin to albumin ratio in critically ill
patients with cirrhosis: Insights from MIMIC-IV database.
PLoS One. 2025;20:e0334591.
Transplant Proc
- ZUBKOV MR, Moore HB, Baimas-George M, Arrigain S, et al
Is Model for End-stage Liver Disease 3.0 Better Than Model for End-stage Liver
Disease? Evaluating the Association of Liver Disease Severity Scores With
Perioperative Complications in Liver Transplant Recipients.
Transplant Proc. 2025 Sep 23:S0041-1345(25)00442.
- GUO WB, Guo XJ, Zheng MY, Xie XC, et al
Analysis of the Cost-Effectiveness of Treatment Strategies for Acute-on-Chronic
Liver Failure.
Transplant Proc. 2025;57:1554-1559.
- SAEGUSA Y, Ohira M, Honmyo N, Nakano R, et al
Outcomes of Liver Transplantation Among Patients Diagnosed With Acute-on-Chronic
Liver Failure: A Single-Center Experience.
Transplant Proc. 2025 Jul 17:S0041-1345(25)00321.
Transplantation
- HASJIM BJ, Paukner M, Kwong AJ, Bhat M, et al
Impact of the 6-mo Wait Policy on Transplantation, Resection, and Ablation
Outcomes for Patients With Hepatocellular Carcinoma: A National Cancer Database
Analysis.
Transplantation. 2025 Oct 13. doi: 10.1097/TP.0000000000005536.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016